Premium
Upregulation of surrogate markers of inflammation and thrombogenesis in ESRD patients: pathophysiologic and therapeutic implications
Author(s) -
Nelson Kelly,
Cunanan Josephine,
Hoppensteadt Debra,
Bansal Vinod,
Bajwa Randeep,
Fareed Jawed
Publication year - 2007
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.21.6.lb123-b
Subject(s) - medicine , inflammation , end stage renal disease , gastroenterology , surrogate endpoint , myeloperoxidase , d dimer , pathogenesis , c reactive protein , immunology , hemodialysis
Thrombotic and inflammatory processes play a major role in the pathogenesis of End Stage Renal Disease (ESRD). This investigation will profile thrombotic and inflammatory markers in ESRD patients undergoing therapeutic dialysis. Methods: Blood samples drawn prior to dialysis in 161 patients with ESRD and from 100 healthy males and females were analyzed for such markers of thrombogenesis as Thrombin‐Antithrombin III Complex (TAT), prothrombin fragment (F1.2), D‐Dimer, and Fibrinopeptide A (FPA). Inflammatory markers such as CD40 Ligand, Myeloperoxidase (MPO), TNFα, and MCP‐1 were also measured. Results: Results were compiled for each of the individual markers in terms of mean +/− 1 standard deviation. The mean for each of the markers was also compared with the mean of the normal values. Fold increase or decrease in each of the markers was calculated and are given in the following table.Conclusions: These studies show that ESRD patients exhibit activation of the coagulation and inflammatory processes. Of the coagulation markers TAT showed the most striking change, whereas in the inflammatory marker profiling TNF demonstrated marked elevation. Profiling of these markers in ESRD may be useful in risk stratification and selection of treatment options to optimize clinical management.